← Latest news 
Dr Reddy’s wins approval for generic oral semaglutide after head to head trial
Health & Fitness
Published on 24 April 2026
Trial showed non inferiority versus Rybelsus
Dr Reddy’s has received regulatory approval in India to roll out its generic oral semaglutide. The approval follows a head to head comparative study in India that found the formulation non inferior to Novo Nordisk’s Rybelsus. The company says this clinical evidence helped it secure approval under India’s biosimilar regulatory pathway.
- Dr Reddy’s gets India nod to launch generic oral semaglutide
- Head to head study showed non inferiority to Rybelsus
- Approval comes under India’s biosimilar regulatory pathway
Read the full story at The Economic Times
This summarization was done by Beige for a story published on 
The Economic Times